Business Wire

VR and AR Examined from All Angles at IBC2017

6.7.2017 20:38 | Business Wire

Jaa

Virtual Reality (VR), Augmented Reality (AR) and Mixed Reality (MR) will come under real-world scrutiny at IBC2017, with opportunities throughout the show to learn more about these new technologies - from their current place in the market to the opportunities they offer, as well as examining technological challenges and user experiences.

Rikard Steiber, President Viveport and SVP Virtual Reality at HTC Vive, will give a conference keynote presentation on 16 September looking at the road ahead for VR. The session will look at the emerging swathe of consumer devices and services, such as the Viveport VR app store, as well as showcasing successful VR experiences across platforms, from entertainment to sports content.

While revenue forecasts for VR and AR over the next three years run into the billions, many companies are still hesitant to invest. The panel discussion “Leaving the Hype Behind: Next Frontier in VR, AR, MR and Other Realities in Between” on 17 September, promises an illuminating session on the realities of VR and AV. Success stories, insight into the projects in R&D, and a pragmatic discussion about what will it take for VR and AR technologies to reach their potential will all feature. Panellists include Edward Tang, Co-Founder and CTO of Avegant, a company that has developed ground-breaking Retinal Imaging Technology; Leen Segers, Co-Founder and CEO of LucidWeb, a pioneer in VR content development and distribution; and Tony Mugavero, CEO of LittlStar, a global network platform dedicated to VR and 360 content.

Also taking place on 17 September, the Startup Forum offers an invaluable day for established media houses, startups and investors working in VR, AR and MR to share their opinions on the future for these advanced media technologies. Speakers include Marco DeMiroz, Co-Founder of The Venture Reality Fund (The VR Fund), a company that invests in early-stage VR, AR and MR startups.

IBC has also curated a choice selection of conference papers on this hot topic, in a session entitled “VR and AR – The Production, The Potential and The Pitfalls”. Speakers will share some of the lessons that have been learned so far, as well as discussing the exciting potential of live-action VR captured with camera arrays, the potential adverse effects of VR and AR – and how to avoid them.

In addition, the IBC Future Zone is set to deliver the latest ideas and innovations as a specially selected group of companies, including BBC R&D, Generic Robotics, NHK. Sennheiser and Immersia TV, showcases technologies including mixed reality, 3D audio and holographic projection, with a focus on multi-sensory virtual worlds and imagery of the future.

The IBC Future Zone is also home to the IBC Future Reality Theatre. Free to attend for all IBC attendees, the Theatre looks beyond current technology, identifying state of the art concepts and inventions and helping to map future applications and market sectors. Confirmed companies speaking include, Adobe, Live Planet, Nokia, V-Nova and Mettle.

“VR, AR and MR are everywhere at IBC this year, from the conference to the Future Zone to the exhibition halls,” said Michael Crimp, CEO, IBC. “There’s a real sense of excitement around these new technologies and IBC provides an ideal opportunity to learn more about the new opportunities that are available for driving innovative content and creating new revenue streams.”

## ENDS ##

Notes to Editors:

About IBC

IBC is the world’s leading media, entertainment and technology show. It attracts 55,000+ attendees from more than 170 countries and combines a highly respected and peer-reviewed conference with an exhibition that showcases more than 1,700 leading suppliers of state of the art electronic media and entertainment technology.

IBC2017 Dates

Conference: 14 – 18 September 2017

Exhibition: 15 – 19 September 2017

For more information about IBC2017 visit: show.ibc.org/

Contact information

Bubble Communications
Louise Wells
E: louisew@bubbleagency.com
T: +44 7718 985 252

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 16:00Tiedote

Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of

Acxiom Launches Connected Spaces27.7.2017 15:30Tiedote

Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative

Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 15:08Tiedote

On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to

European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 14:05Tiedote

Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney

Subscription Period for Superior Industries’ Tender of UNIWHEELS AG’s Shares to Close Monday, July 31, 201727.7.2017 09:00Tiedote

Superior Industries International, Inc. (NYSE:SUP), one of the world’s largest manufacturers of aluminum wheels, reiterated today that the subscription period for the tender offer to acquire all remaining outstanding shares of UNIWHEELS AG (“UNIWHEELS”) will close Monday, July 31, 2017. On June 30, 2017, Superior announced it had commenced a tender offer to acquire the remaining 954,920 shares held by the public shareholders, which represents approximately 7.7% of the total outstanding shares of UNIWHEELS, for cash consideration of 247.87zl per share. Superior acquired the other approximately 92.3% of the outstanding shares through a tender offer that was settled on May 30, 2017, where the public shareholders also received cash consideration of 247.87zl per share. Following the settlement of the tender offer, Superior will finalize the proceedings to delist UNIWHEELS’ common stock from

Ipsen Delivers Strong Sales Growth of 18.8%1 in the First Half of 2017 and Upgrades Its Guidance for Full Year 201727.7.2017 08:00Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2017. H1 2017 Highlights Strong operating performance of 18.8%1 Group sales growth and Core Operating Income margin improvement by 1.2 points to 26.2% of sales Specialty Care sales growth of 23.1%1 reflects continued Somatuline® momentum and includes contribution of key new products Cabometyx® and Onivyde® Consumer Healthcare sales growth of 1.3%1 including contribution of newly acquired products Upgraded full year 2017 guidance of Specialty Care sales growth greater than 24.0%1, slight growth1 of Consumer Healthcare sales, and Core Operating Income margin greater than 25.0% o

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme